Style | Citing Format |
---|---|
MLA | Hedayati N, et al.. "Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity." Discover Oncology, vol. 16, no. 1, 2025, pp. -. |
APA | Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, Dorostgou Z, Alaei E, Alimohammadi M, Rahimzadeh P, Taheriazam A, Hashemi M (2025). Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity. Discover Oncology, 16(1), -. |
Chicago | Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, Dorostgou Z, et al.. "Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity." Discover Oncology 16, no. 1 (2025): -. |
Harvard | Hedayati N et al. (2025) 'Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity', Discover Oncology, 16(1), pp. -. |
Vancouver | Hedayati N, Safari MH, Milasi YE, Kahkesh S, Farahani N, Khoshnazar SM, et al.. Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity. Discover Oncology. 2025;16(1):-. |
BibTex | @article{ author = {Hedayati N and Safari MH and Milasi YE and Kahkesh S and Farahani N and Khoshnazar SM and Dorostgou Z and Alaei E and Alimohammadi M and Rahimzadeh P and Taheriazam A and Hashemi M}, title = {Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity}, journal = {Discover Oncology}, volume = {16}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Hedayati N AU - Safari MH AU - Milasi YE AU - Kahkesh S AU - Farahani N AU - Khoshnazar SM AU - Dorostgou Z AU - Alaei E AU - Alimohammadi M AU - Rahimzadeh P AU - Taheriazam A AU - Hashemi M TI - Modulation of the Pi3k/Akt Signaling Pathway by Resveratrol in Cancer: Molecular Mechanisms and Therapeutic Opportunity JO - Discover Oncology VL - 16 IS - 1 SP - EP - PY - 2025 ER - |